RegMed Investors’ (RMi) pre-open: controlled response of bomb futures

June 23, 2025 7:45am

The restrained tone for markets this week foreshadows tensions and uncertainty of the Middle East “events” as well as the coming economic data and earnings reports set for release

While I write, selling into volatility carries risk after 2 weeks of sessions with 5 negative, 3 positive, 1 neutral and 1 holiday closes

Pre-open Indications: 2 Sell into Strength and 3 Positive

No false narratives or fake news; to read insights and analysis on the latest sector action, check out Pre-Open Brief

Never leave an investor uninformed!

Remember that overnight and pre-open actions’ futures and markets doesn’t necessarily translate into actual trading in today’s market session.

“I also hate to be so negative or contrarian but, this is a NO spin zone and truth is its product; I can always be WRONG but, I am mostly EARLY!”

My interpretation of the morning’s numbers is written to be informative; it’s built on what happened to make “it” happen today!

Friday’s night’s … RegMed Investors (RMi) Closing Bell: Luckily, the canopy opened … https://www.regmedinvestors.com/articles/13968   

RegMed Investors (RMi) Research Note: Harvard Apparatus GT (OTCQB): PONZI Scheme at its best or was convicted Bernie Madoff also resurrected … https://www.regmedinvestors.com/articles/13812

Monday: The pre-open Dow futures are DOWN -0.19% or (-82 points), the S&P futures are DOWN -0.12% or (-7 points) and the Nasdaq futures are DOWN -0.15% or (-33 points)

• Stock futures were flipping, now negative ahead of Monday’s session,
• European markets started the week lower,
• Asia-Pacific markets mostly decline.

Henry’omics: We need to more than consider the economic environment to comprehend the micro re “our” universe of cell and gene therapy companies

• Friday: The Dow closed UP +35.18 points or +0.08%, the S&P closed DOWN -13.03 points or -0.22% while the Nasdaq closed DOWN -98.86 points or -0.51%
• Thursday was market holiday
• Last week: The S&P 500 lost -0.2%, Dow had a 0.2% gain and the Nasdaq advanced +0.2%
• The previous week: The S&P 500 lost -0.4%, the Dow fell 1.3% while the Nasdaq slid -0.6%

Economic Data Docket: S&P Flash U.S. manufacturing and services PMI plus Existing home sales

Q2 – June – 1 market holiday, 5 negative, 1 neutral and 9 positive closes

• May – 1 market holiday, 10 negative and 11 positive closes
• Q2 - April – 10 negative and 11 positive closes

Companies in my headlights – It’s your decision; I provide ideas and context

I post about “indication intelligence” looking toward investment conferences … to assist investors with insight into sector vulnerabilities and strengths.  A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.

• Daily indications and the thoughts of expectation with the aftermarket blanking while the pre-open waits for …  any solidity, it is still a mix of ups, downs and just uncertainty

Pre-open Indications:

Alnylam Pharmaceuticals (ALNY) closed down -$2.62 after Thursday’s holiday and Wednesday’s +$3.61 with a positive +$1.56 or +0.50% aftermarket

uniQure NV (QURE) closed down -$0.89 after Thursday’s holiday, Wednesday’s +$0.31 after Tuesday’s -$0.32 after Monday’s -$0.23 with a positive +0.09 or +0.63% pre-open

Sell into Strength: Agenus (AGEN) closed up +$0.31 after Thursday’s holiday, Wednesday’s -$0.31, Tuesday’s -$0.36 and Monday’s +$0.44 with a neutral pre-open

Sell into Strength: CRISPR Therapeutics (CRSP) closed down -$0.18 after Thursday’s holiday, Wednesday’s +$1.24, Tuesday’s +$1.61 and Monday’s +$0.22 with a positive +$0.14 or +0.32% pre-open

Ionis Pharmaceuticals (IONS) closed up +$0.40 after Thursday’s holiday, Wednesday’s +$0.86, Tuesday’s +$0.91 and Monday’s -$0.35 with a positive +$0.59 or +1.58% aftermarket

The BOTTOM LINE: New week <6/23 to 6/27> slowing coming to a month’s end <Monday, 6/30>.

• The market’s recent calm – so far, in the face of rising geopolitical threats has left traders with a conundrum:
• Sell into volatility and risk being blindsided should the Middle East conflict escalate; or buy into unpredictability after the cell and gene therapy sector has been bled value…
• While the oil market is still likely to have the biggest reaction to the escalating conflict, equities may see an initial jump in volatility as traders try to digest the risks. Oil has surged 11% since Israel launched airstrikes on Iran a little more than a week ago, with crude volatility soaring to levels not seen since Russia’s invasion of Ukraine in 2022. By contrast, the S&P 500 Index is down just 1.3%. <Yahoo Finance>

A reading of the Fed's preferred inflation gauge will highlight economic releases in the upcoming week.

• Updates on activity in the manufacturing and services sectors, consumer confidence, and the final reading of Q1 economic growth are also expected.
• A 2-day semiannual monetary policy testimony from Fed Chair Powell will also be in focus starting on Tuesday.

Last week, 6/16 – 6/20 started with a Monday positive close … followed by Tuesday’s negative close … and a Wednesday’s positive close and a Thursday market holiday and Fridays’ negative close.

Interesting Info this month of June: The M&A list evolves: Blueprint Medicine (BPMC) by Bristol Meyers (BMY), Sage Therapeutics by Supernus Pharmaceuticals (SUPN), CureVac (CVAC) by BioNTech (BNTX) and now Verve Therapeutics (VERV) by Eli Lilly (LLY)

June ’25: understand the “flow” of markets, the cell and gene therapy sector and economic karma…

• 6/20 - Friday closed negative with 14 positive, 18 negative and 3 flats
• 5/19 – Thursday was a market holiday
• 6/18 – Wednesday closed positive with 21 positive, 11 negative and 3 flats
• 6/17 - Tuesday closed negative with 10 positive, 23 negative and 2 flats
• 6/16 - Monday closed positive with 20 positive, 11 negative and 4 flats

• 6/13 - Friday closed negative with 5 positive, 25 negative and 5 flats
• 6/12 – Thursday closed negative with 7 positive, 23 negative and 5 flats
• 6/11 – Wednesday closed negative with 6 positive, 25 negative and 4 flats
• 6/10 - Tuesday closed positive with 17 positive, 15 negative and 3 flats
• 6/9 - Monday closed neutral with 16 positive, 16 negative and 3 flats

• 6/6 – Friday negative with 4 positive, 28 negative and 3 flats
• 6/5 - Thursday closed positive with 16 positive, 15 negative and 4 flats
• 6/4 – Wednesday closed positive with 18 positive, 13 negative and 4 flats
• 6/3 - Tuesday closed positive with 24 positive, 8 negative and 3 flats
• 6/2 - Monday closed positive with 25 positive, 7 negative and 3 flats

Reiterating, “There are always some big ifs, especially given some of the headlines that could emanate after a past few months of news flatulence.

• Still a believer after I wrote, about June… “Get back-in and re-test the sector waters after May’s cell and gene therapy sector ‘s month alternations, nibble!  Some believe in a “June Swoon;” however, June will be no better or worse than any other month. Although, I consider the so-called summer rally after the peripatetic or wandering.”

As always, brace ourself for more volatility, economics and their down trending affect?

Welcome to my world of defining the “grey’ in our universe!

• The sector is what it is, until it isn’t and even then, it doesn’t seem to be… as NOT much changes as the sector’s share pricing rides the waves of volatility, algorithms, electronic trading and short covering.
• I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.  Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities.

I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed.